Use of endostatin peptides for the treatment of fibrosis
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsCarol A. Feghali-Bostwick, Yukie Yamaguchi
Life of this patent
Estimating the term…
Abstract
C-terminal endostatin polypeptides are disclosed herein. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed. Uses of these polypeptide, polynucleotides and expression vectors include the treatment of fibrosis in a subject. Thus, methods are provided for treating fibrosis, including fibrosis of the skin and/or the lung.
Claims26
An isolated polypeptide, comprising at least 10 consecutive amino acids and at most 47 amino acids of the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO:
- 2, wherein the polypeptide:
- a) comprises amino acids 145-153 of SEQ ID NO:
- 2;
- b) has anti-fibrotic activity;
- and
- c) does not comprise amino acids 1-92 of SEQ ID NO:
- 2;
- and
- wherein the polypeptide is optionally amidated.
An isolated polypeptide consisting essentially of:
- a) the amino acid sequence set forth as amino acids 133-141 of SEQ ID NO:
- 2;
- or
- b) the amino acid sequence set forth as amino acids 145-153 of SEQ ID NO:
- 2;
- and
- wherein the polypeptide is optionally amidated.
Dependencies are inferred from the claim text.